Page 7 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA
P. 7
Comparison of variant calling tools for muta on analysis of BRCA1 and BRCA2 genes in pa ents with epithelial ovarian
cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Expression and heteromeriza on of adenosine A2A and dopamine D2 G protein-coupled receptors in neuroendocrine
tumors of the lung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Detec on of viral proteins in locally advanced rectal cancer pa ent samples by mass spectrometry – predic ve poten al
for response to neoadjuvant chemoradiotherapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Prognos c Value of Combined Hematological/Biochemical Indexes and Tumor Clinicopathologic Features in Colorectal
Cancer Pa ents—A Pilot Single Center Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
The Polymorphisms of Genes Encoding An oxidant Enzymes Modulate the Risk for Tes cular Germ Cell Tumor. . . . . 79
Complementarity of miR-203a-3p and ETS-1 sequences may infl uence agressiveness of papillary thyroid carcinoma. 79
Characteriza on of nischarin expression in pancrea c ductal adenocarcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Expression profi le of CD81 gene transcripts in colorectal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Gene c polymorphisms of enzymes involved in redox homeostasis can infl uence survival in smokers and overweight
pa ents with prostate cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Expression of long non-coding RNA HOTAIR in rectal cancer as a poten al predictor of response to chemoradiotherapy
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Prognos c poten al of redox status, SLFN11, and PD-L1 in colorectal cancer pa ents . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Interleukin-6, a poten al plasma biomarker for diagnosis and prognosis of thyroid neoplasms . . . . . . . . . . . . . . . . . . . 83
The eff ect of tyrosine kinase inhibitors in high-grade glioma pa ent-derived cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
The signifi cance of interleukin-8 in hormonally dependent early breast cancer – associa on with the established
parameters ER/PR and HER2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Variant rs745430558 in the SMAD4 gene promoter as a biomarker for adenocarcinoma of the pancreas . . . . . . . . . . 85
Eff ect of BET inhibitors on cancer stem cells sorted from primary oral cancer cell culture. . . . . . . . . . . . . . . . . . . . . . . . 85
Precision medicine in gastrointes nal oncology – gemcitabine-based systemic chemotherapy in pa ents with advanced/
metasta c pancrea c carcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Precision medicine in gastrointes nal oncology – therapeu c approach in pa ents with braf mutant metasta c colorectal
cancer: a retrospec ve analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Iron metabolism in the prognosis of epithelial ovarian cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Can serum HER2 tes ng add prognos c value to rou ne ssue HER2 analysis for primary breast cancer pa ents?. . . 87
Prognos c signifi cance of the localiza on of the primary tumor and HER2-receptor expression in KRAS wild-type
metasta c colorectal cancer treated with an -EGFR therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Expression Profi le of Sex Hormone Receptors in Head and Neck Cancer: Unraveling Gender Dispari es. . . . . . . . . . . . 88
Circula ng cytokine changes in BRAFwt MM pa ents during an -PD-1 therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
Prognos c signifi cance of pathologically detected extramural venous invasion (EMVI) in rectal carcinoma . . . . . . . . . 90
Genomic instability as a prognos c marker in malignant brain cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Head and neck cancer: single- and two-stage reconstruc on . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Simultaneous EGFR L858R and T790M muta ons in treatment-naïve metasta c lung adenocarcinoma: a case study and
therapeu c implica ons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
